AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Sold by Raymond James & Associates

Raymond James & Associates lessened its holdings in AbCellera Biologics Inc. (NASDAQ:ABCLFree Report) by 69.5% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 16,132 shares of the company’s stock after selling 36,692 shares during the period. Raymond James & Associates’ holdings in AbCellera Biologics were worth $74,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ABCL. Baillie Gifford & Co. boosted its position in AbCellera Biologics by 33.0% in the 2nd quarter. Baillie Gifford & Co. now owns 26,364,751 shares of the company’s stock valued at $170,316,000 after buying an additional 6,535,100 shares during the period. ArrowMark Colorado Holdings LLC purchased a new stake in shares of AbCellera Biologics during the 2nd quarter worth $26,519,000. State Street Corp lifted its position in shares of AbCellera Biologics by 1,087.3% during the 2nd quarter. State Street Corp now owns 3,194,309 shares of the company’s stock worth $34,019,000 after purchasing an additional 2,925,279 shares during the last quarter. Lazard Asset Management LLC lifted its position in shares of AbCellera Biologics by 997.1% during the 1st quarter. Lazard Asset Management LLC now owns 3,189,837 shares of the company’s stock worth $31,100,000 after purchasing an additional 2,899,091 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of AbCellera Biologics by 385.5% during the 1st quarter. Renaissance Technologies LLC now owns 2,617,603 shares of the company’s stock worth $25,522,000 after purchasing an additional 2,078,400 shares during the last quarter. Hedge funds and other institutional investors own 47.39% of the company’s stock.

AbCellera Biologics Trading Up 2.2 %

Shares of ABCL opened at $5.02 on Friday. The firm’s 50-day moving average is $5.34 and its two-hundred day moving average is $5.19. AbCellera Biologics Inc. has a twelve month low of $3.87 and a twelve month high of $10.59. The firm has a market capitalization of $1.46 billion, a P/E ratio of -11.16 and a beta of 0.38.

Analyst Upgrades and Downgrades

ABCL has been the subject of a number of research reports. Piper Sandler reissued an “overweight” rating and issued a $20.00 price target on shares of AbCellera Biologics in a research report on Friday, October 13th. Benchmark cut shares of AbCellera Biologics from a “buy” rating to a “hold” rating in a research report on Monday, November 6th. Piper Sandler Companies reaffirmed an “overweight” rating and issued a $20.00 target price on shares of AbCellera Biologics in a report on Friday, October 13th. KeyCorp assumed coverage on shares of AbCellera Biologics in a report on Tuesday, December 5th. They issued an “overweight” rating and a $6.00 target price for the company. Finally, Bloom Burton reaffirmed a “buy” rating on shares of AbCellera Biologics in a report on Friday, November 3rd. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, AbCellera Biologics presently has an average rating of “Moderate Buy” and a consensus price target of $20.38.

Get Our Latest Report on AbCellera Biologics

AbCellera Biologics Profile

(Free Report)

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets.

See Also

Institutional Ownership by Quarter for AbCellera Biologics (NASDAQ:ABCL)

Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.